Telmisartan to Prevent Recurrent Stroke and Cardiovascular Events
نویسندگان
چکیده
منابع مشابه
Telmisartan to prevent recurrent stroke and cardiovascular events.
BACKGROUND Prolonged lowering of blood pressure after a stroke reduces the risk of recurrent stroke. In addition, inhibition of the renin-angiotensin system in high-risk patients reduces the rate of subsequent cardiovascular events, including stroke. However, the effect of lowering of blood pressure with a renin-angiotensin system inhibitor soon after a stroke has not been clearly established. ...
متن کاملTelmisartan to prevent recurrent stroke: the PRoFESS study: was the baby thrown out with the bathwater?
In retrospect, the choice of PRoFESS as the acronym for this trial may be considered unwise. The dictionary definition of the verb “to profess” is “to declare or to claim, often insincerely or falsely.” What does PRoFESS declare and can we believe the claim? Blood pressure reduction initiated several months after stroke reduces cardiovascular complications, including recurrent stroke.1 Would ea...
متن کاملDoes lowering blood pressure prevent recurrent stroke?
Question In patients with a history of stroke or transient ischaemic attack, can further stroke be prevented by lowering blood pressure, even when it is not elevated? Commentary Rationale for the trial About one in five stroke survivors suffer another stroke in the five years after the initial incident. 1 Blood pressure is related in a continuous manner to the risk of an initial stroke, but man...
متن کاملCorrection to: Lifestyle Interventions to Prevent Cardiovascular Events After Stroke and Transient Ischemic Attack: Systematic Review and Meta-Analysis.
In the article by Deijle et al, “Lifestyle Interventions to Prevent Cardiovascular Events After Stroke and Transient Ischemic Attack: Systematic Review and Meta-Analysis,” which published online ahead of print on December 6, 2016, and appeared in the January 2017 issue of the journal (Stroke. 2017;48:174–179. DOI: 10.1161/STROKEAHA.116.013794), a correction is needed. On page 174, the following...
متن کاملTelmisartan shown to reduce cardiovascular death, myocardial infarction and stroke in ACE-intolerant high-risk patients.
The TRANSCEND study, using telmisartan, is the first long-term outcome study of angiotensin receptor blocker (ARB) therapy in a group of high-risk, ACE-intolerant patients and has shown telmisartan’s positive benefits over a range of outcomes, including the composite of cardiovascular death, myocardial infarction and stroke. The study results were announced by Prof Teo Koon of Mc Master Univers...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: New England Journal of Medicine
سال: 2008
ISSN: 0028-4793,1533-4406
DOI: 10.1056/nejmoa0804593